UroGen Pharma Ltd. has announced the issuance of inducement restricted stock units (RSUs) to 40 new employees as part of their compensation package. These employees will aid in the commercialization of the company's products, Jelmyto® and ZUSDURI™, as well as the development of UroGen's pipeline. Up to 67,700 ordinary shares of UroGen are available upon the vesting and settlement of the RSUs, which will vest equally over three years, with one-third vesting each year on the anniversary of the vesting date.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524278-en) on September 08, 2025, and is solely responsible for the information contained therein.